Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52‑Week Open‑Label Safety Study of Tezepelumab in Japanese Patients with Severe Asthma
jRCT2080224709Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tezepelumab in severe asthma, sponsored by AstraZeneca. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on jRCT2080224709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224709.